References
- Collier F, Smith RC, Morton CA. Diagnosis and management of hidradenitis suppurativa. BMJ 2013;346:f2121–6
- van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. 2011;164:1292–8
- van Rappard DC, Limpens J, Mekkes JR. The off-label treatment of severe hidradenitis suppurativa with TNF-α inhibitors: a systematic review. J Dermatolog Treat. 2013;24:392–404
- Hofmann SC, Saborowski V, Lange S, et al. Expression of innate defense antimicrobial peptides in hidradenitis suppurativa. J Am Acad Dermatol. 2012;66:966–74
- Scheinfeld N. Hidradenitis suppurativa: a practical review of possible medical treatments based on over 350 hidradenitis patients. Dermatol Online J. 2013;19:1
- Nassif A, Coignard H, Join-Lambert O, Lortholary O. Complete remission of severe hidradenitis suppurativa obtained in 4 patients using wide-spectrum antimicrobial treatment. J Am Acad Dermatol. 2012;66:P5181.AB46
- Menon S, Verdolini R. Alitretinoin in the treatment of hidradenitis suppurativa: an insight. J Am Acad Dermatol. 2013;68:P6570.AB8
- Uzun G, Ozdemir Y, Mutluoğlu M, Güleç B. Hyperbaric oxygen therapy as an adjunct to surgical treatment of extensive hidradenitis suppurativa. World J Surg. 2010;34:861–2